• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Tao Synergies Inc.

    10/24/25 4:12:47 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAOX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001571934
    Synaptogenix, Inc.
    NEUROTROPE BIOSCIENCE, INC.
    SYNAPTOGENIX, INC.
    NEUROTROPE BIOSCIENCE INC.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    TAO Synergies Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    TAO Synergies Inc.
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    NEW YORK NEW YORK 10036 973-242-0005

    3. Related Persons

    Last Name First Name Middle Name
    WEINSTEIN ROBERT
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    CHIEF FINANCIAL OFFICER
    Last Name First Name Middle Name
    SILVERMAN JOSHUA
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    EXECUTIVE CHAIRMAN
    Last Name First Name Middle Name
    SINGER WILLIAM
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    BERNSTEIN BRUCE
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    EPHRON ROBERT
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
    X
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-10-13    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    GP NURMENKARI INC. 000153480
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    22 ELIZABETH ST.
    City State/Province/Country ZIP/Postal Code
    NORWALK CONNECTICUT 06854
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    ILLINOIS
    NEW YORK
    OHIO

    13. Offering and Sales Amounts

    Total Offering Amount $11,000,000 USD
    or    Indefinite
    Total Amount Sold $11,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    7

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $880,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    TAO Synergies Inc. /s/ Robert Weinstein ROBERT WEINSTEIN CHIEF FINANCIAL OFFICER 2025-10-24

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $TAOX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAOX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TAOX
    SEC Filings

    View All

    SEC Form D filed by Tao Synergies Inc.

    D - TAO Synergies Inc. (0001571934) (Filer)

    10/24/25 4:12:47 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tao Synergies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - TAO Synergies Inc. (0001571934) (Filer)

    10/14/25 6:12:21 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tao Synergies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - TAO Synergies Inc. (0001571934) (Filer)

    8/29/25 5:00:44 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that through acquisition and staking, the Company's total TAO holdings have increased to 54,058 tokens. This further solidifies TAO Synergies' position as the largest publicly traded pure-play holder of Bittensor (TAO), the groundbreaking protocol powering decentralized AI innovation. TAO Synergies continues to execute on its mission to democratize access to decentralized AI for retail and institutional investors alike, while capturin

    10/20/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Announces $11 Million Private Placement

    Financing supported by existing stockholders, TAO Strategy Advisor James Altucher, and new investor DCG NEW YORK, Oct. 13, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that it has entered into a securities purchase agreement with existing investors, James Altucher and a new investor, DCG, for a $11 million financing. "TAO Synergies' latest financing further supports its continuing strategic investments not only in TAO tokens, but also in potential opportunities to earn revenue and accrue additional TAO within the Bi

    10/13/25 5:09:00 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

    New digital hub to educate, engage, and connect the growing TAO community and decentralized AI contributors NEW YORK, Sept. 22, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced the launch of "The Tao Daily," a comprehensive media, news, and insight platform dedicated to Bittensor (TAO) and the TAO ecosystem.  The TAO Daily is designed not only to be up to date on all news related to TAO, but also to educate the market about the Bittensor ecosystem, its native token TAO, and the specialized subnets within the TAO network

    9/22/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weinstein Robert covered exercise/tax liability with 4,000 shares and was granted 10,000 shares, increasing direct ownership by 57% to 16,574 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:14:09 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Singer William S. was granted 15,000 shares and covered exercise/tax liability with 6,000 shares, increasing direct ownership by 85% to 19,566 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:13:16 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Silverman Joshua was granted 100,000 shares and covered exercise/tax liability with 40,000 shares, increasing direct ownership by 225% to 86,681 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:12:16 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Financials

    Live finance-specific insights

    View All

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care